Abstract
The enzyme 3–hydroxy–3–methylglutaryl coenzyme A (HMG–CoA) reductase, involved in de novo cholesterol synthesis and cell–cycle progression, was identified as a potential mediator of the growth inhibitory effects of retinoic acid on human neuroblastoma. Lovastatin, a nonreversible inhibitor of HMG–CoA reductase, induced extensive cytotoxicity that was restricted to drug–resistant P–glycoprotein–expressing neuroblastoma cell lines. This response was potentiated by dibutyryl cyclic AMP but not retinoic acid. Patients with advanced–stage metastatic neuroblastoma often display an acquired chemoresistant phenotype, which may in part be mediated by P–glycoprotein. Our studies support the application or use of HMG–CoA reductase inhibitors as potential therapeutic agents in the treatment of these patients who are refractory to chemotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adam, A. & Hocholzer, L. Ganglioneuroblastoma of the posterior mediastinum. Cancer 47, 373–381 (1983).
Bolande, R.P. Spontaneous regression and cytodifferentiation of cancer in early life: the oncogenic grace period. Surv. Synthet. Pathol. Res. 4, 296–311 (1985).
Evans, A.E., Gerson, J. & Schnanfer, L. Spontaneous regression of neuroblastoma. Natl. Cancer Inst. Monogr. 44, 49–54 (1976).
Shimada, H. et al. Histopathologic prognostic factors on neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and age-linked classification of neuroblastoma. J. Natl. Cancer Inst. 73 405–416 (1984).
Tsokos, M., Scarpa, S., Ross, R.A. & Triche, T.J. Differentiation of human neuroblastoma recapitulates neural crest development. Am. J. Pathol. 128, 484–496 (1987).
Yeger, H. et al. Phenotypic and molecular characterization of inducible human neuroblastoma cell lines. Differentiation 39, 216–227 (1988).
Woods, W.G., Lemieux, B. & Tuchman, M. Neuroblastoma represents distinct clinical-biological entities: A review and perspective from the Quebec neuroblastoma screening project. Pediatrics 89, 114–118 (1992).
Goldstein, L.J. et al. Expression of the multidrug resistance, MDR1, gene in neuroblastoma. J. Clin. Oncol. 8, 128–136 (1990).
Bardow, S.B. et al. Expression of the multidrug resistance-associated protein (MRP). gene correlates with amplification and overexpression of the N-myconcogene in childhood neuroblastoma. Cancer Res. 54, 5036–5040 (1994).
Gottesman, M.M. & Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385–427 (1993).
Chan, H.S.L. et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N. Engl. J. Med. 325, 1608–1614 (1991).
Bourhis, J. et al. Correlation of MDR1 gene expression with chemotherapy in neuroblastoma. J. Natl. Cancer Inst. 81, 1401–1405 (1989).
Dimitroulakos, J., Squire, J., Pawlin, G. & Yeger, H. NUB-7: A stable I-type human neuroblastoma cell line inducible along N- and S-type cell lineages. Cell Growth Differ. 5, 373–384 (1994).
Liang, P. & Pardee, A.B. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 257, 967–971 (1992).
Goldstein, J.L. & Brown, M.S. Regulation of the mevalonate pathway. Nature 343, 425–430 (1990).
Corsini, A., Maggi, F.M. & Catapano, A.L. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol. Res. 31, 9–27 (1995).
Ramharack, R., Tam, S.P. & Deeley, R.G. Characterization of three distinct size classes of human 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA: Expression of the transcripts in hepatic and nonhepatic cells. DNA Cell Biol. 9, 677–690 (1990).
Wimalasena, J., Meehan, D. & Cavallo, C. Human epithelial ovarian cancer cell steroid secretion and its control by gonadotrophins. Gynecol. Oncol. 41, 56–63 (1991).
Kleinert, R. Immunohistochemical characterization of primitive neuroectodermal tumors and their possible relationship to the stepwise ontogenic development of the central nervous system. Acta Neuropathol. 82, 502–515 (1991).
Thiele, C.J., Reynolds, C.P. & Israel, M.A. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 313, 404–406 (1985).
Arey, J.B. The lipidoses: Morphologic changes in the nervous system in Gaucher's disease, GM2-gangliosidoses and Neimann-Pick disease. J. Clin. Lab. Sci. 5, 475–482 (1975).
Kerr, J.F.R., Winterford, C.M. & Harmon, B.V., Its clinical significance in cancer and cancer therapy. Cancer 73, 2013–2026 (1994).
Piacentini, M., Fesus, L. & Melino, G. Multiple cell cycle access to the apoptotic death programme in human neuroblastoma cells. FEBS Lett. 320, 150–154 (1993).
Keyomarsi, K., Sandoval, L., Band, V. & Pardee, A.B. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 51, 3602–3609 (1991).
Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Meth. 65, 55–63 (1983).
Ramani, P. & Dewchand, H. Expression of mdrl/P-glycoprotein and p110 in neuroblastoma. J. Pathol. 175, 13–22 (1995).
Rocchi, P. et al. Growth inhibitory and differentiating effects of sodium butyrate on human neuroblastoma cells in culture. Anticancer Res. 12, 917–920 (1992).
Gibbs, J.B., C-terminal processing enzymes — new drug targets? Cell 65, 1–4 (1991).
Kohl, N.E. et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Med. 1, 792–797 (1995).
Maltese W.A. Inhibitation of farneysltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice Nature Med. 1 792 – 797 (1995).
DeLuca, L. Retinoids and their receptors in differentiation, embryogenesis and neoplasia. FASEB J. 5, 2924–2933 (1991).
Britton, G. Structure and properties of carotenoids in relation to function. FASEB J. 9 1551–1558 (1995).
Karp, J.E. & Broder, S. Molecular foundations of cancer: New targets for intervention. Nature Med. 1, 309–320 (1995).
Gottesman, M.M. The role of cAMP in regulating tumor cell growth. Cancer Surv. 5, 291–308 (1986).
Gaetano, C., Matsumoto, K. & Thiele, C.J. In vitro activation of distinct molecular and cellular phenotypes after induction of differetiation in a human neuroblastoma cell line. Cancer Res. 52, 4402–407 (1992).
Maltese, W.A., Defendini, R., Green, R.A., Sheridan, K.M. & Donley, D.K. Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive in hibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. J. Clin. Invest. 76 1748–1754 (1985).
Chervinsky, D.S., Brecher, M.L. & Hoelcle, M.J. Cremophor-EL enhances taxol efficacy in a multidrug resistant C1300 neuroblastoma cell line. Anticancer Res. 13 93–96 (1993).
Holmberg, M., Sandberg, C., Nygren, P. & Larsson, R. Effects of lovastatin on a human myeloma cell line: Increased sensitivity of a multidrug resistant subline that expresses P-glycoprotein. Anti-cancer Drugs 5, 598–600 (1994).
Tsujita, Y. et al. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: Tissue selective inhibitor of of sterol synthesis and hypolipidemic effect on various animal species. Biochim. Biophys. Acta 877, 50–60 (1986).
Lange, Y. & Steck, T.L. Cholesterol homeostasis: modulation by amphiphiles. J. Biol. Chem. 269, 29371–29374 (1994).
Abermayor, E. The effects of retinoic acid on the in vitro and in vivo growth of neuroblastoma cells. Laryngoscope 102, 1133–1149 (1992).
O'Dorisio, M.S., Fleshman, D.J., Qualman, S.J. & O'Dorisio, T.M. Vasoactive intestinal peptide: autocrine growth factor in neuroblastoma. Regul. Pept. 37 231–236 (1992).
Helson, L., Kelson, C., Peterson, R.F. & Susanta, K.D. A rationale for the treatment of metastatic neuroblastoma. J. Natl. Cancer Inst. 57, 727–729 (1976).
Yeger, H., Mor, O., Pawlin, G., Kaplinsky, C. & Shiloh, Y. Importance of phenotypic and molecular characterization for identification of a neuroepithelioma tumor cell line, NUB-20. Cancer Res. 50, 2794–2802 (1990).
Seeger, R.C. et al. Morphology, growth, chromosomal pattern, and fibrinolytic activity of two new human neuroblastoma cell lines. Cancer Res. 37 1364–1371 (1977).
Murakami, T., Ohmori, H., Tsuda, T. & Higashi, K. The effect of changes in the N-myc products on the gene expression of heat shock protein (HSP-70). and nucleolin during differentiation of neuroblastoma cells. Progr. Clin. Biol. Res. 366 65–70 (1991).
Sekiguchi, M., Oota, T., Sakakibara, K., Inui, N. & Fujii, G. Establishment and characterization of a human neuroblastoma cell line in tissue culture. Jpn. J. Exp. Med. 49, 67–83 (1979).
Imashuka, S., Inui, A., Nakamura, T., Tanaka, J. & Miyake S. Catecholamine metabolism in tissue culture cells of a neuroblastoma. J. Clin. Endocrinol. Metab. 36 931–936 (1973).
Cohn, S.L. et al. High levels of N-myc protein in a neuroblastoma cell line lacking N-myc amplification. Progr. Clin. Biol. Res. 366, 21–27 (1991).
Biedler, J.L., Helson, L. & Spengler, B.A. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continous culture. Cancer Res. 33, 2643–2652 (1973).
Tumilowicz, J.J., Nichols, W.W., Cholon, J.J. & Greene, A.E. Definition of a continuous cell line derived from neuroblastoma. Cancer Res. 30, 2110–2118 (1970).
Keyomarsi, K., Sandoval, L., Band, V. & Pardee, A.B. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 51, 3602–3609 (1991).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dimitroulakos, J., Yeger, H. HMG–CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P–glycoprotein–expressing cells. Nat Med 2, 326–333 (1996). https://doi.org/10.1038/nm0396-326
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0396-326
This article is cited by
-
Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment
Signal Transduction and Targeted Therapy (2021)
-
Drug Repurposing in Medulloblastoma: Challenges and Recommendations
Current Treatment Options in Oncology (2021)
-
A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies
Journal of Translational Medicine (2016)
-
Exploiting the critical perioperative period to improve long-term cancer outcomes
Nature Reviews Clinical Oncology (2015)
-
Cholesterol oxidase from Bordetella species promotes irreversible cell apoptosis in lung adenocarcinoma by cholesterol oxidation
Cell Death & Disease (2014)